Dr Tony Radford
Tony co-founded and was the Chief Executive Officer of Cellestis, which developed and commercialized QuantiFERON Gold for diagnosis of tuberculosis (TB) infection. Cellestis was acquired by QIAGEN NV in 2011 for US$355m.
Tony holds a PhD in Microbiology from Latrobe University, is an Officer of the Order of Australia for distinguished service to science and global public health and is a Fellow of the Academy of Technology and Engineering. Tony is also a director of Genetic Signatures and joined the Ellume Board in June 2017.